Leon M Smith, Ii

USPTO Granted Patents = 40 (Patent Applications = 6)

Average Co-Inventor Count = 6.5

ph-index = 7

Forward Citations = 191(Granted Patents)

Company Filing History:

35 out of 3,681

Bristol-myers Squibb Compnay

Years Active: 2006-2025

where 'Filed Patents' based on already Granted Patents

40 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12428421 - Pyrimidinones as factor XIA inhibitors (2025-09-30),

2. 11053247 - Pyrimidinones as factor XIA inhibitors (2021-07-06),

3. 10899743 - Substituted glycine derived FXIA inhibitors (2021-01-26),

4. 10829501 - Spiroheptane salicylamides and related compounds as inhibitors of ROCK (2020-11-10),

5. 10611776 - Spiroheptane salicylamides and related compounds as inhibitors of rock (2020-04-07),

6. 10336754 - Pyrimidinones as factor XIa inhibitors (2019-07-02),

7. 10336730 - Substituted glycine derived FXIA inhibitors (2019-07-02),

8. 10273236 - Macrocyclic factor XIa inhibitors bearing heterocyclic groups (2019-04-30),

9. 10208021 - Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors (2019-02-19),

10. 10160750 - Diamide macrocycles as factor XIa inhibitors (2018-12-25),

11. 10000466 - Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors (2018-06-19),

12. 9951071 - Dihydropyridone P1 as factor XIa inhibitors (2018-04-24),

13. 9944625 - Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors (2018-04-17),

14. 9902742 - Macrocycles as factor XIa inhibitors (2018-02-27),

15. 9777001 - Macrocycles with aromatic P2' groups as factor xia inhibitors (2017-10-03),

Title: Leon M. Smith, II: Innovating in Hematology and Inflammation Treatment

Introduction: Leon M. Smith, II, based in Somerset, NJ, is a prolific inventor with an impressive portfolio of 39 patents. His work primarily focuses on developing innovative solutions for treating thromboembolic and inflammatory disorders, showcasing his commitment to advancing medical science.

Latest Patents: Among his recent contributions to the field, Smith has developed patents for "Pyrimidinones as Factor XIa Inhibitors" and "Substituted Glycine Derived FXIa Inhibitors." Both inventions present compounds designed to be selective inhibitors of factor XIa, along with dual inhibitors of FXIa and plasma kallikrein. These compounds and their pharmaceutical compositions aim to provide novel methods for treating various thromboembolic and inflammatory conditions.

Career Highlights: Throughout his career, Leon M. Smith, II has made significant strides in the pharmaceutical industry, working with esteemed companies such as Bristol-Myers Squibb Company and Amgen Inc. His innovative spirit and dedication have positioned him as a valuable asset in drug development and research.

Collaborations: Smith has also collaborated with notable colleagues, including Donald J. P. Pinto and James R. Corte. Their combined expertise has likely contributed to the success of Smith's various patented inventions and advancements in therapeutic treatments.

Conclusion: With a strong background in pharmaceuticals and a dedication to innovation, Leon M. Smith, II continues to make impactful contributions in the realm of medical treatments. His extensive patent portfolio reflects his commitment to improving health outcomes and exemplifies the spirit of innovation in addressing complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

6 patents pending:

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.